11:55 AM EST - Immunovaccine Inc. : Announced positive topline results from its Phase 1 trial evaluating the safety and immunogenicity of DPX-RSV, its DepoVax™-based, small B cell epitope peptide vaccine candidate for respiratory syncytial virus. Immunovaccine Inc.
shares T.IMV are trading up $0.02 at $0.70.
